Cell Therapy · global
Replacing Lost Photoreceptors: BlueRock Retinal Therapy Receives US and European Orphan Drug Designations
Lemiretprocel, which aims to replace cells lost from the retina with stem cell-derived cells, is undergoing early human trials. US and European orphan drug designations mark regulatory progress for this rare disease therapy, but whether it can safely improve vision remains a question for clinical data to answer.
As the retina’s photoreceptors gradually disappear, the challenge for treatment extends beyond protecting the remaining cells to whether lost function can be restored. BlueRock Therapeutics’ cell therapy lemiretprocel is attempting to restore vision through this approach; on September 30, the company announced that the therapy, which is still in early clinical trials, had received orphan drug designations in the United States and Europe.
Lemiretprocel, known by the development code OpCT-001, is an investigational cell therapy derived from induced pluripotent stem cells (iPSCs). Its concept is to replace cells lost from the retina with new functional cells, exploring a potential treatment for primary photoreceptor diseases. This is a development goal; the therapy has not yet been shown to restore patients’ vision.
BlueRock is a wholly owned, independently operated subsidiary of Bayer. Both the company announcement and an S&P Capital IQ report published on MarketScreener on October 1 stated that the US FDA designation covers retinitis pigmentosa and cone-rod dystrophy. In Europe, the designation covers syndromic and nonsyndromic inherited retinal diseases with predominantly rod phenotypes, as well as nonsyndromic diseases with predominantly cone phenotypes. The disease classifications and scope of coverage in the two regions are not identical.
The therapy is currently being evaluated in the Phase 1/2a CLARICO study, which includes patients with retinitis pigmentosa, Usher syndrome, and cone-rod dystrophy. According to the design published by the company, this first-in-human, multicenter study is expected to enroll up to approximately 54 adults, initially focusing on safety and tolerability before exploring visual function and anatomical changes following cell implantation.
The first stage plans four escalating dose cohorts, with progression to higher doses only after an acceptable safety signal emerges at a lower dose. A subsequent stage will select two doses based on these results and randomly assign participants to receive treatment. This arrangement helps explore the relationship between dose and clinical outcomes, but it compares different doses and cannot directly be regarded as evidence of established efficacy.
The announcement centers on progress in regulatory designation and does not disclose new patient efficacy results. Orphan drug designation does not equate to marketing approval, nor does it mean that safety or efficacy has been confirmed. For lemiretprocel, the next key step remains human trials: whether the implanted cells can safely persist, function, and translate into improvements in vision that patients can actually perceive.